Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2013 --- Glioblastoma has an angiogenic component, as the disease manifests itself as a focal lesion with central necrosis surrounded by an angiogenic tumor rim . Genentech and Roche took advantage of this with the data from the phase II BRAIN study (AVF3708g), which suggested that single-agent Avastin® (bevacizumab) was active, with a six-month PFS rate of 42.6% and was slightly higher (50.3%) in combination with irinotecan.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2013 --- The role of Programmed Death-1 (PD-1) in suppression of antitumor immunity was one of the hottest topics at the 2012 American Society of Clinical Oncology (ASCO) annual meeting and excitement around this topic has only intensified at ASCO 2013 as this story continues to unfold. PD-1 is a key immune checkpoint receptor expressed on activated T-cells and binding of PD-1 to its ligand, PD-L1, results in suppression of the immune response.
    Continue Reading > | Go comment! | Share
  • Neesha Suvarna
    Oncology Conference Insight: ASCO 2013 --- Activation of the PI3K-AKT-mTOR pathway has been implicated as one of several potential mechanisms for acquired resistance to HER2-targeted and hormone therapy in breast cancer. Preclinical and clinical results support investigation into whether acquired resistance can be overcome by downstream inhibition of this pathway.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2013 --- Although first-line combination chemotherapy with a platinum (carboplatin or cisplatin) plus a taxane (primarily paclitaxel) is very successful at producing high response rates in first-line advanced ovarian cancer patients, the vast majority (up to 70%1) of these patients still experience a recurrence. Based on this high unmet need to extend progression free survival (PFS) in these first-line patients, maintenance therapy in now utilized in some advanced ovarian cancer patients.
    Continue Reading > | Go comment! | Share
  • User Not Found
    Oncology Conference Insight: ASCO 2013 --- One of the hottest presentations this year is the results from a German cooperative group-sponsored FIRE-3 study (n=592), comparing first-line FOLFIRI in combination with low-dose (5 mg/kg every two weeks) Avastin (bevacizumab, Roche/Genentech) or standard dose Erbitux (cetuximab, Bristol Myers-Squibb, Eli Lilly, Merck KGaA) in metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.
    Continue Reading > | Go comment! | Share